These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 12522573)

  • 21. Dopaminergic drugs in development for Parkinson's disease.
    Korczyn AD
    Adv Neurol; 2003; 91():267-71. PubMed ID: 12442685
    [No Abstract]   [Full Text] [Related]  

  • 22. Treatment of Parkinson's disease in Thailand: review of the literature and practical recommendations.
    Bhidayasiri R; Ling H
    J Med Assoc Thai; 2009 Jan; 92(1):142-54. PubMed ID: 19260256
    [TBL] [Abstract][Full Text] [Related]  

  • 23. S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: II. Actions in rodent, primate, and cellular models of antiparkinsonian activity in comparison to ropinirole.
    Millan MJ; Di Cara B; Hill M; Jackson M; Joyce JN; Brotchie J; McGuire S; Crossman A; Smith L; Jenner P; Gobert A; Peglion JL; Brocco M
    J Pharmacol Exp Ther; 2004 Jun; 309(3):921-35. PubMed ID: 14978195
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The chemical biology of clinically tolerated NMDA receptor antagonists.
    Chen HS; Lipton SA
    J Neurochem; 2006 Jun; 97(6):1611-26. PubMed ID: 16805772
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A hospital-based study: risk factors in development of motor complications in 555 Parkinson's patients on levodopa therapy.
    Benbir G; Ozekmekçi S; Apaydin H; Delil S; Erginöz E
    Clin Neurol Neurosurg; 2006 Dec; 108(8):726-32. PubMed ID: 16564615
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neuroprotective effects of a selective N-methyl-D-aspartate NR2B receptor antagonist in the 6-hydroxydopamine rat model of Parkinson's disease.
    Leaver KR; Allbutt HN; Creber NJ; Kassiou M; Henderson JM
    Clin Exp Pharmacol Physiol; 2008 Nov; 35(11):1388-94. PubMed ID: 18785982
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Parkinson's disease. Diagnosis and the initiation of therapy.
    Bhat V; Weiner WJ
    Minerva Med; 2005 Jun; 96(3):145-54. PubMed ID: 16175158
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neuroprotective effect of L-DOPA co-administered with the adenosine A2A receptor agonist CGS 21680 in an animal model of Parkinson's disease.
    Agnati LF; Leo G; Vergoni AV; Martínez E; Hockemeyer J; Lluis C; Franco R; Fuxe K; Ferré S
    Brain Res Bull; 2004 Aug; 64(2):155-64. PubMed ID: 15342103
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dopamine agonists in the treatment of Parkinson's disease.
    Bonuccelli U; Pavese N
    Expert Rev Neurother; 2006 Jan; 6(1):81-9. PubMed ID: 16466315
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bilateral deep brain stimulation in Parkinson's disease: a multicentre study with 4 years follow-up.
    Rodriguez-Oroz MC; Obeso JA; Lang AE; Houeto JL; Pollak P; Rehncrona S; Kulisevsky J; Albanese A; Volkmann J; Hariz MI; Quinn NP; Speelman JD; Guridi J; Zamarbide I; Gironell A; Molet J; Pascual-Sedano B; Pidoux B; Bonnet AM; Agid Y; Xie J; Benabid AL; Lozano AM; Saint-Cyr J; Romito L; Contarino MF; Scerrati M; Fraix V; Van Blercom N
    Brain; 2005 Oct; 128(Pt 10):2240-9. PubMed ID: 15975946
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Duodenal levodopa infusion improves quality of life in advanced Parkinson's disease.
    Antonini A; Mancini F; Canesi M; Zangaglia R; Isaias IU; Manfredi L; Pacchetti C; Zibetti M; Natuzzi F; Lopiano L; Nappi G; Pezzoli G
    Neurodegener Dis; 2008; 5(3-4):244-6. PubMed ID: 18322402
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CNS dopamine oxidation and catechol-O-methyltransferase: importance in the etiology, pharmacotherapy, and dietary prevention of Parkinson's disease.
    Zhu BT
    Int J Mol Med; 2004 Mar; 13(3):343-53. PubMed ID: 14767563
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Drug selection and timing of initiation of treatment in early Parkinson's disease.
    Schapira AH; Olanow CW
    Ann Neurol; 2008 Dec; 64 Suppl 2():S47-55. PubMed ID: 19127579
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prevention of dyskinesia by an NMDA receptor antagonist in MPTP monkeys: effect on adenosine A2A receptors.
    Morissette M; Dridi M; Calon F; Hadj Tahar A; Meltzer LT; Bédard PJ; Di Paolo T
    Synapse; 2006 Sep; 60(3):239-50. PubMed ID: 16739115
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of levodopa-induced motor complications.
    Stocchi F; Tagliati M; Olanow CW
    Mov Disord; 2008; 23 Suppl 3():S599-612. PubMed ID: 18781681
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role of dopamine agonists in Parkinson's disease: an update.
    Bonuccelli U; Pavese N
    Expert Rev Neurother; 2007 Oct; 7(10):1391-9. PubMed ID: 17939774
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of a selective glutamate antagonist on L-dopa-induced dyskinesias in drug-naive parkinsonian monkeys.
    Hadj Tahar A; Grégoire L; Darré A; Bélanger N; Meltzer L; Bédard PJ
    Neurobiol Dis; 2004 Mar; 15(2):171-6. PubMed ID: 15006686
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of motor dysfunction in Parkinson's disease: an overview.
    Thobois S; Delamarre-Damier F; Derkinderen P
    Clin Neurol Neurosurg; 2005 Jun; 107(4):269-81. PubMed ID: 15885384
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of receptor heterodimers in the development of L-dopa-induced dyskinesias in the 6-hydroxydopamine rat model of Parkinson's disease.
    Fiorentini C; Busi C; Spano P; Missale C
    Parkinsonism Relat Disord; 2008; 14 Suppl 2():S159-64. PubMed ID: 18638717
    [TBL] [Abstract][Full Text] [Related]  

  • 40. NMDA antagonists as Parkinson's disease therapy: disseminating the evidence.
    Majláth Z; Vécsei L
    Neurodegener Dis Manag; 2014; 4(1):23-30. PubMed ID: 24640976
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.